321 related articles for article (PubMed ID: 26694375)
21. Treatment-resistant schizophrenia characterised by dopamine supersensitivity psychosis and efficacy of asenapine.
Takao N; Murai T; Fujiwara H
BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33849886
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia.
Nakata Y; Kanahara N; Kimura H; Watanabe H; Iyo M
Int Clin Psychopharmacol; 2017 May; 32(3):169-173. PubMed ID: 28067751
[TBL] [Abstract][Full Text] [Related]
23. Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia.
Takase M; Kanahara N; Oda Y; Kimura H; Watanabe H; Iyo M
J Psychopharmacol; 2015 Apr; 29(4):383-9. PubMed ID: 25735995
[TBL] [Abstract][Full Text] [Related]
24. Impact of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: An analysis of multi-factors predicting long-term prognosis.
Yamanaka H; Kanahara N; Suzuki T; Takase M; Moriyama T; Watanabe H; Hirata T; Asano M; Iyo M
Schizophr Res; 2016 Feb; 170(2-3):252-8. PubMed ID: 26775264
[TBL] [Abstract][Full Text] [Related]
25. A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis.
Kimura H; Kanahara N; Komatsu N; Ishige M; Muneoka K; Yoshimura M; Yamanaka H; Suzuki T; Komatsu H; Sasaki T; Hashimoto T; Hasegawa T; Shiina A; Ishikawa M; Sekine Y; Shiraishi T; Watanabe H; Shimizu E; Hashimoto K; Iyo M
Schizophr Res; 2014 May; 155(1-3):52-8. PubMed ID: 24667073
[TBL] [Abstract][Full Text] [Related]
26. Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials.
Lockwood JT; Remington G
Expert Opin Emerg Drugs; 2015 Sep; 20(3):407-21. PubMed ID: 26166007
[TBL] [Abstract][Full Text] [Related]
27. Dopamine D2 receptors as treatment targets in schizophrenia.
Seeman P
Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
[TBL] [Abstract][Full Text] [Related]
28. A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis: The ROADS study.
Niitsu T; Hata T; Nishimoto M; Hosoda Y; Kimura A; Oda Y; Suzuki M; Takase N; Seki R; Fujita K; Endo M; Yoshida T; Inoue M; Hattori N; Murakami T; Imamura Y; Ogawa K; Fukami G; Sato T; Kawasaki Y; Hashimoto T; Ishikawa M; Shiina A; Kanahara N; Iyo M;
Asian J Psychiatr; 2020 Oct; 53():102369. PubMed ID: 32920492
[TBL] [Abstract][Full Text] [Related]
29. Case series on aripiprazole and dopamine supersensitivity psychosis.
Russell G; Reinfeld S; Kam O; Lee G; Weiss M; Koola MM
Int Clin Psychopharmacol; 2022 May; 37(3):122-128. PubMed ID: 35143441
[TBL] [Abstract][Full Text] [Related]
30. Clonazepam improves dopamine supersensitivity in a schizophrenia patient: a case report.
Fukai M; Hirosawa T; Takahashi T; Kaneda R; Kikuchi M; Minabe Y
Ther Adv Psychopharmacol; 2017 Mar; 7(3):113-117. PubMed ID: 28348731
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.
Howes OD; Egerton A; Allan V; McGuire P; Stokes P; Kapur S
Curr Pharm Des; 2009; 15(22):2550-9. PubMed ID: 19689327
[TBL] [Abstract][Full Text] [Related]
32. Are dopamine D2 receptors out of control in psychosis?
Seeman P
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():146-52. PubMed ID: 23880595
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy of modified electroconvulsive therapy and long-acting injectable aripiprazole for dopamine supersensitivity psychosis: a case report.
Matsuzaka Y; Noguchi M; Kanamura S; Maeda K; Hisano T; Tanaka D; Ando Y; Yamamoto T; Morimoto Y; Ozawa H; Otsuka T
Neurocase; 2022 Jun; 28(3):310-313. PubMed ID: 35993136
[TBL] [Abstract][Full Text] [Related]
34. Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.
Zhang JP; Robinson DG; Gallego JA; John M; Yu J; Addington J; Tohen M; Kane JM; Malhotra AK; Lencz T
Schizophr Bull; 2015 Nov; 41(6):1248-55. PubMed ID: 26320194
[TBL] [Abstract][Full Text] [Related]
35. Upregulation of heat-shock protein HSP-70 and glutamate transporter-1/glutamine synthetase in the striatum and hippocampus in haloperidol-induced dopamine-supersensitivity-state rats.
Kimura M; Oda Y; Hirose Y; Kimura H; Yoshino K; Niitsu T; Kanahara N; Shirayama Y; Hashimoto K; Iyo M
Pharmacol Biochem Behav; 2021 Dec; 211():173288. PubMed ID: 34653399
[TBL] [Abstract][Full Text] [Related]
36. Reduction of dopamine and glycogen synthase kinase-3 signaling in rat striatum after continuous administration of haloperidol.
Kimura M; Oda Y; Kimura H; Nangaku M; Hirose Y; Niitsu T; Kanahara N; Shirayama Y; Hashimoto K; Iyo M
Pharmacol Biochem Behav; 2021 Mar; 202():173114. PubMed ID: 33485878
[TBL] [Abstract][Full Text] [Related]
37. Reduction of Severity of Recurrent Psychotic Episode by Sustained Treatment with Aripiprazole in a Schizophrenic Patient with Dopamine Supersensitivity: A Case Report.
Tadokoro S; Nonomura N; Kanahara N; Hashimoto K; Iyo M
Clin Psychopharmacol Neurosci; 2017 Feb; 15(1):79-81. PubMed ID: 28138118
[TBL] [Abstract][Full Text] [Related]
38. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
39. The impacts of dopamine D2 receptor polymorphism and antipsychotic dosage on dopamine supersensitivity psychosis in schizophrenia.
Takase M; Kanahara N; Oda Y; Niitsu T; Watanabe H; Iyo M
Schizophr Res; 2017 Dec; 190():182-183. PubMed ID: 28285026
[No Abstract] [Full Text] [Related]
40. Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade.
Ebdrup BH; Raghava JM; Nielsen MØ; Rostrup E; Glenthøj B
J Psychiatry Neurosci; 2016 Mar; 41(2):133-41. PubMed ID: 26599135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
